Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist
SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND application of Phase 1 Multiple Ascending Dose (MAD) study for ID110521156, an oral...
2024-08-28 10:43
1973
Ildong Pharmaceutical starts Phase 1 study of new diabetes therapy in Germany
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- A Phase 1 study on new drug candidate IDG16177 of novel oral treatment for type 2 diabetes, which is being developed by Ildong Pharmaceutical, is initiated inGermany. On June 28th (local time), Ildong Pharmaceutical obtained approval for the Phas...
2021-07-01 21:00
2394
